Please assess the completion status of the following clinical trial:

Trial Title: Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signature of informed consent~* COPD patients with age raging from 50 to 85 years old~* Patients with at least a history of COPD of one year~* COPD patients clinically stable in the last three months~* COPD subjects with Forced Expiratory Volume at one second (FEV1)\<50% of predicted value~* COPD subjects with Residual Volume (RV) \>125% predicted value~* FEV1/Forced Vital Capacity (FVC) \<88% (males) or \<89% (females) of Low Levels of Normality (LLN)~* COPD former or active smokers with at least a smoking history of 20 pack year~Exclusion Criteria:~* Acute Bronchial Exacerbation at recruitment~* Fertile women with age between 18 and 50 years old or with active period~* Pregnancy~* Subjects enrolled in other clinical trials or that have taken part in one of them in the month preceding the enrollment.~* FEV1/FVC more than 70% of predicted value in basal conditions~* FEV1 more than 70% of predicted value in basal conditions~* Known deficit of alpha 1 antitrypsin~* Subjects that underwent a Lung Volume Reduction Surgery (LVRS)~* Subjects with known positivity to Human Immunodeficiency Virus (HIV)~* Misuse of alcool or drugs~* Lack of compliance in performing respiratory tests~* Subjects not capable to follow the study prescriptions because of psychic disorders or language problems.~* Long Term Oxygen Therapy with flows \> 6 litres per minute (l/min) at rest

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Aclidinium - Glycopyrronium (Type: EXPERIMENTAL): Patients will assume Aclidinium Bromide 322 dry powder by Genuair inhaler and Glycopyrronium 44 dry powder inhaler by Breezehaler inhaler (placebo) after 72 hours from inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted), they will receive Glycopyrronium Bromide 322 mcg via Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo).
- Glycopyrronium - Aclidinium (Type: EXPERIMENTAL): Patients will assume Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo) after 72 hours of inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted) they will receive Aclidinium Bromide 322 mcg via Genuair inhaler and Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler (placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).